A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer

NCT06879041 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

136

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Castration-Resistant Prostate Cancer

Interventions

DRUG: AZD2287
DRUG: AZD2275
DRUG: AZD2284

Sponsor

AstraZeneca

Collaborators

[object Object]